Growth hormone is not secreted continuously — it is released in discrete pulses, and the pulsatile pattern itself carries biological information that sustained GH exposure does not replicate. This distinction is among the most consequential and most frequently overlooked in GH axis research design.
The Physiology of Pulsatile GH Secretion
Growth hormone secretion from the anterior pituitary is controlled by two hypothalamic signals acting in opposition: growth hormone-releasing hormone (GHRH) stimulates GH release; somatostatin (SRIF) inhibits it. GH pulsatility emerges from the cyclical interplay between these opposing systems — when somatostatin tone falls and GHRH tone rises, the pituitary responds with a GH pulse. When somatostatin rebounds, GH secretion stops.
In humans, this produces approximately 6–12 distinct GH pulses per 24 hours with a characteristic circadian pattern: the largest pulse occurs during the first slow-wave sleep cycle (typically 1–2 hours after sleep onset), with smaller pulses distributed across the day. Between pulses, GH levels fall near zero — the trough is as physiologically important as the peak. Critically, the pituitary’s GH reservoir is replenished between pulses, requiring somatostatin-driven quiescence for resynthesis.
Why the Pulse Pattern Matters: GH Receptor Biology
GH receptor (GHR) is not indifferent to the pattern of GH delivery — it is exquisitely sensitive to it. The key findings from decades of rodent research:
The Two Axes of GH Stimulation: GHRH-R and GHSR-1a
Two independent receptor pathways stimulate pituitary GH release. Understanding both is essential for interpreting secretagogue research and designing protocols that use them alone or in combination:
| Pathway | Receptor | Ligands (research tools) | Intracellular signal | Effect on somatostatin |
|---|---|---|---|---|
| GHRH axis | GHRH-R (Gs-coupled GPCR) | Sermorelin, CJC-1295 No DAC | cAMP↑ → PKA → GH synthesis and secretion | Neutral — does not directly suppress somatostatin |
| Ghrelin/GHRP axis | GHSR-1a (Gq-coupled GPCR) | Ipamorelin, GHRP-2, GHRP-6 | IP3/PKC → Ca2+ → GH vesicle exocytosis | Suppresses somatostatin — disinhibits pituitary |
| Combined stimulation | Both receptors simultaneously | CJC-1295 + ipamorelin (most common combination) | Both pathways converge additively on secretion | Both GHRH-R activation and somatostatin suppression maximise pulse amplitude |
The physiological relevance of combined GHRH+GHRP stimulation: endogenous GH pulses are generated by simultaneous GHRH release and somatostatin withdrawal — the two events co-occur physiologically. CJC-1295 (GHRH axis) + ipamorelin (GHSR-1a axis, somatostatin suppression) most closely replicates this dual physiological trigger, producing synergistically amplified GH pulses that better model the endogenous pulse generation mechanism than either secretagogue alone.
How Different Research Compounds Affect GH Pulsatility
| Compound | Effect on pulsatility | Half-life | Best use case |
|---|---|---|---|
| Recombinant HGH (rhGH) | Eliminates pulsatility — produces pharmacokinetic peak/trough | ~3–4 hours | Hypophysectomised models; precise dose control required; pulsatility not the study variable |
| Sermorelin (GHRH 1-29) | Preserves pulsatility; physiological pulse amplitude | ~10–15 min | Closest replication of endogenous GHRH pulsatile trigger; short-acting |
| CJC-1295 No DAC | Preserves pulsatility; amplified pulse amplitude | ~25–30 min | GHRH axis stimulation with longer action than sermorelin; combined with ipamorelin |
| Ipamorelin | Preserves pulsatility; selective GHSR-1a; no cortisol/prolactin | ~2 hours | Selective GHSR-1a stimulation; minimal HPA axis confound; combined with CJC-1295 |
| GHRP-2 | Preserves pulsatility; GHSR-1a + moderate cortisol stimulation | ~1–2 hours | When HPA co-stimulation is acceptable or is the study endpoint |
| GHRP-6 | Preserves pulsatility; GHSR-1a + higher cortisol/prolactin + ghrelin appetite | ~1–2 hours | When ghrelin axis appetite stimulation is part of the research model |
Practical Implications for Protocol Design
If pulsatility is the independent variable: Use secretagogues, not rhGH. The choice of secretagogue determines which pathway(s) you are stimulating — sermorelin for pure GHRH-R, ipamorelin for selective GHSR-1a, CJC-1295 + ipamorelin for the combined physiological model.
If sustained GH elevation is required: rhGH is the cleaner tool for studies where the independent variable is simply elevated circulating GH concentration, not the pulsatile pattern. This is appropriate for hypophysectomised models, dose-response studies needing precise plasma GH titration, or studies where pituitary function is not intact.
If the GH axis itself is the research subject: Use secretagogues to preserve the intact pituitary-hypothalamic feedback loop. rhGH suppresses endogenous GH secretion through negative feedback (increases somatostatin tone, reduces GHRH release) — any study of the intact GH axis should use compounds that work through the axis, not around it.
Controlling for the somatostatin variable: In studies where somatostatin tone varies across experimental groups (e.g., stress models, fasting models, disease models), the differential GH response to secretagogues may confound between-group comparisons. In such cases, rhGH provides more consistent GH delivery independent of somatostatin variation — but at the cost of disrupting axis physiology.
Frequently Asked Questions
What is GH pulsatility?
GH pulsatility refers to the episodic, pulsed pattern of growth hormone secretion from the anterior pituitary. Rather than being secreted continuously, GH is released in discrete bursts — approximately 6–12 pulses per 24 hours in humans, with the largest pulse occurring during slow-wave sleep. Between pulses, circulating GH levels fall near zero. This on-off pulsatile pattern is physiologically critical — the pulse frequency and amplitude independently regulate GH receptor activity, IGF-1 production, and body composition effects.
Why does GH pulsatility matter for research?
GH receptor (GHR) responds differently to pulsatile vs sustained GH elevation. Pulsatile stimulation maintains receptor sensitivity and produces distinct gene expression patterns compared to continuous GH exposure. In rodents, pulsatile GH patterns regulate sex-specific liver gene expression — male rats have high-amplitude, low-frequency pulses producing masculine body composition; female rats have more frequent lower-amplitude pulses producing a different metabolic phenotype. Research using continuous GH delivery (e.g. subcutaneous infusion or minipump) vs pulsatile secretagogues produces mechanistically distinct results that are not interchangeable.
Do GH secretagogues preserve GH pulsatility?
Yes. GH secretagogues (sermorelin, CJC-1295 No DAC, ipamorelin, GHRP-2, GHRP-6) stimulate pituitary GH release rather than delivering exogenous GH directly. Because they work by triggering the pituitary’s own secretion, they preserve the pulsatile output pattern — each secretagogue dose triggers a GH pulse. The pulse amplitude is amplified above baseline, but the pulsatile structure is maintained. By contrast, exogenous rhGH produces a pharmacokinetic peak-and-trough profile that does not replicate physiological pulsatility.
What is the difference between GHRH and GHRP mechanisms for GH release?
GHRH (growth hormone-releasing hormone) and GHRP/ghrelin agonists are two independent stimulatory pathways for pituitary GH release. GHRH binds the GHRH receptor (GHRH-R) on somatotrophs, activating cAMP and increasing GH synthesis and secretion. GHRPs/ghrelin agonists bind the growth hormone secretagogue receptor (GHSR-1a), activating a separate signalling pathway (IP3/PKC) that independently stimulates GH release and also suppresses somatostatin. When both pathways are activated simultaneously (e.g. CJC-1295 + ipamorelin), the GH pulse amplitude is synergistically greater than either alone — because GHRH-R activation and GHSR-1a activation converge additively on somatotroph secretion while GHSR-1a also suppresses the somatostatin brake.
What is somatostatin and how does it regulate GH?
Somatostatin (SRIF — somatotropin release-inhibiting factor) is a 14-amino acid peptide produced by hypothalamic periventricular neurons that tonically inhibits GH secretion from the pituitary. GH pulsatility is generated by cyclical variations in the balance between GHRH stimulation and somatostatin inhibition — when somatostatin tone falls, the pituitary responds to GHRH with a GH pulse. GHRP/ghrelin agonists partially work by suppressing somatostatin, which disinhibits the pituitary and allows a larger GH pulse in response to any GHRH signal present.
Sermorelin · CJC-1295 No DAC · Ipamorelin · GHRP-2 · GHRP-6 · HGH